BMRN
BioMarin Pharmaceuticals Inc
stock NASDAQ

$CAMP has cash to last them until Q2 2026. They will be releasing preclinical data on the 13th-17th of this month and then are expecting another catalyst in Q2 which could be any week now, the initiation of expansion into Phase 1b clinical trial of CMP-CPS-001 in female OTC heterozygotes in Australia expected in Q2 2025, with Europe to follow pending CTA clearance. with even more data to be released later in the year.
The company IPO'd at $11 per share and is now all the way down near $2. They secured collaboration worth $370M at the end of last year with $BMRN which is a $12B company. (info is on their 10Q filing from this time period)
They have $64M cash with ZERO long term debt and just received a $17 and $18 Price target in March from verified wall street analysts with multiple other buy ratings. The stock was trading around $6 per share a few weeks ago and is now bottomed out with many catalysts underway.
What's even more intriguing is just recently they added industry leaders to join their team. Some of them had executive roles at $150B+ companies and they all have insane track records. They are building a dream team here which is very rare for a penny stock..
I think this one is super undervalued and since they have cash for the next year there isn't a need for dilution.
Shorts have completely beaten this one down since the IPO and currently it’s showing 13% of the float is being shorted on ORTEX , but it’s way higher than that due to naked shorts, it’s obvious this one has been manipulated down just look at the volume today .
I could see this going back to $5+

$CAMP has cash to last them until Q2 2026. They will be releasing preclinical data on the 13th-17th of this month and then are expecting another catalyst in Q2 which could be any week now, the initiation of expansion into Phase 1b clinical trial of CMP-CPS-001 in female OTC heterozygotes in Australia expected in Q2 2025, with Europe to follow pending CTA clearance. with even more data to be released later in the year.
The company IPO'd at $11 per share and is now all the way down near $2. They secured collaboration worth $370M at the end of last year with $BMRN which is a $12B company. (info is on their 10Q filing from this time period)
They have $64M cash with ZERO long term debt and just received a $17 and $18 Price target in March from verified wall street analysts with multiple other buy ratings. The stock was trading around $6 per share a few weeks ago and is now bottomed out with many catalysts underway.
What's even more intriguing is just recently they added industry leaders to join their team. Some of them had executive roles at $150B+ companies and they all have insane track records. They are building a dream team here which is very rare for a penny stock..
I think this one is super undervalued and since they have cash for the next year there isn't a need for dilution.

$CAMP has cash to last them until Q2 2026. They will be releasing preclinical data on the 13th-17th of this month and then are expecting another catalyst in Q2 which could be any week now, the initiation of expansion into Phase 1b clinical trial of CMP-CPS-001 in female OTC heterozygotes in Australia expected in Q2 2025, with Europe to follow pending CTA clearance. with even more data to be released later in the year.
The company IPO'd at $11 per share and is now all the way down near $2. They secured collaboration worth $370M at the end of last year with $BMRN which is a $12B company. (info is on their 10Q filing from this time period)
They have $64M cash with ZERO long term debt and just received a $17 and $18 Price target in March from verified wall street analysts with multiple other buy ratings. The stock was trading around $6 per share a few weeks ago and is now bottomed out with many catalysts underway.
What's even more intriguing is just recently they added industry leaders to join their team. Some of them had executive roles at $150B+ companies and they all have insane track records. They are building a dream team here which is very rare for a penny stock..
I think this one is super undervalued and since they have cash for the next year there isn't a need for dilution.
Shorts have completely beaten this one down since the IPO and currently it’s showing 13% of the float is being shorted on ORTEX , but it’s way higher than that due to naked shorts, it’s obvious this one has been manipulated down just look at the volume today .
I could see this going back to $5+

$CAMP has cash to last them until Q2 2026. They will be releasing preclinical data on the 13th-17th of this month and then are expecting another catalyst in Q2 which could be any week now, the initiation of expansion into Phase 1b clinical trial of CMP-CPS-001 in female OTC heterozygotes in Australia expected in Q2 2025, with Europe to follow pending CTA clearance. with even more data to be released later in the year.
The company IPO'd at $11 per share and is now all the way down near $2. They secured collaboration worth $370M at the end of last year with $BMRN which is a $12B company. (info is on their 10Q filing from this time period)
They have $64M cash with ZERO long term debt and just received a $17 and $18 Price target in March from verified wall street analysts with multiple other buy ratings. The stock was trading around $6 per share a few weeks ago and is now bottomed out with many catalysts underway.
What's even more intriguing is just recently they added industry leaders to join their team. Some of them had executive roles at $150B+ companies and they all have insane track records. They are building a dream team here which is very rare for a penny stock..
I think this one is super undervalued and since they have cash for the next year there isn't a need for dilution.